real-time news and commentary for investors
Wednesday, Jul 31
Life Technologies signs licensing agreement with Novartis
- In a move that "represents a significant step in the growth of [the company] from a research tools provider to a leading medical device company," Life Technologies (LIFE) licenses Dynabeads CD3/CD28 CTS to Novartis (NVS +1.1%).
- LIFE will supply NVS with proprietary technology for use in immunotherapeutic applications.
- Specifically, Dynabeads "will be used to isolate, activate and expand T cells" that have been genetically modified to recognize and attack cancer cells. (PR)